WHO ICTRP trial
A PHASE II STUDY EVALUATING THE SAFETY AND EFFICACY OF GLOFITAMAB IN COMBINATION…
NL-OMON56027 · Overview of Medical Research in the Netherlands (NL-OMON) · Recruiting
Key facts
| Trial ID | NL-OMON56027 |
|---|---|
| Public title | A PHASE II STUDY EVALUATING THE SAFETY AND EFFICACY OF GLOFITAMAB IN COMBINATION WITH RITUXIMAB (R) PLUS CYCLOPHOSPHAMIDE, DOXORUBICIN, VINCRISTINE, AND PREDNISONE (CHOP) IN CIRCULATING TUMOR (ct)DNA HIGH-RISK PATIENTS WITH UNTREATED DIFFUSE LARGE B-CELL LYMPHOMA |
| Scientific title | A PHASE II STUDY EVALUATING THE SAFETY AND EFFICACY OF GLOFITAMAB IN COMBINATION WITH RITUXIMAB (R) PLUS CYCLOPHOSPHAMIDE, DOXORUBICIN, VINCRISTINE, AND PREDNISONE (CHOP) IN CIRCULATING TUMOR (ct)DNA HIGH-RISK PATIENTS WITH UNTREATED DIFFUSE LARGE B-CELL LYMPHOMA - GO43075 |
| Primary sponsor | Roche Nederland B.V. |
| Registry | Overview of Medical Research in the Netherlands (NL-OMON) |
| Recruitment status | Recruiting |
| Study type | Interventional |
| Phase | 2 |
| Countries | Denmark;France;Netherlands;Poland;Spain;United States of America |
| Conditions | B-cell lymphoma lymph node cancer;10025320;B-cell lymphoma;lymph node cancer |
| Interventions | Glofitamab will be administered on a step-up dosing schedule, starting on Day 8 of Cycle 3 (2.5 mg), Day 15 of Cycle 3 (10 mg), followed by 30 mg on Day 8 of Cycles 4-6 and Day 1 of Cycles 7-10, with each cycle being 21 days in length… |
| Registration date | Dec 18, 2023 |
| Target size | 2 |
| Secondary IDs | 2021-001647-28;NCT04980222;NL78443.056.21 |
| Registry page | onderzoekmetmensen.nl |
At a glance
- No Results available
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About WHO ICTRP trial registrations
The WHO ICTRP combines trial registrations from primary registries worldwide into a single searchable index. Contact and ethics-committee details are not shown here.
Source: World Health Organization (WHO), International Clinical Trials Registry Platform (ICTRP) · Source date: